Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents

Journal of Medicinal Chemistry

Volumn 57, Issue 19, 2014, Pages 8010-8025

  Chakravarti, Bandana ^a   Akhtar, Tahseen ^a   Rai, Byanju ^a   Yadav, Manisha ^a   Akhtar Siddiqui, Jawed ^a   Dhar Dwivedi, Shailendra Kumar ^a   Thakur, Ravi ^a   Singh, Anup Kumar ^a   Singh, Abhishek Kumar ^a   Kumar, Harish ^a   Khan, Kainat ^a   Pal, Subhashis ^a   Rath, Srikanta Kumar ^a   Lal, Jawahar ^a   Konwar, Rituraj ^a   Trivedi, Arun Kumar ^a   Datta, Dipak ^a   Mishra, Durga Prasad ^a   Godbole, Madan Madhav ^b   Sanyal, Sabyasachi ^a   Chattopadhyay, Naibedya ^a   Kumar, Atul ^a   more..

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b Endocrinology Division CSIR Central Drug Research Institute ^*  (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETHER DERIVATIVE; FLUOROURACIL; GEFITINIB; HYDROXYTAMOXIFEN; NAPHTHALENE DERIVATIVE; OXIME DERIVATIVE; PERTUSSIS TOXIN; PROTEIN TYROSINE KINASE; RALOXIFENE; SALINOMYCIN; THIOARYL NAPHTHYLMETHANONE OXIME ETHER DERIVATIVE; UNCLASSIFIED DRUG; [4 (METHYLTHIO)PHENYL](NAPHTHALEN 1 YL)METHANONE O 2 (DIETHYLAMINO)ETHYL OXIME; 4-(METHYLTHIO)PHENYL)(NAPHTHALEN-1-YL)METHANONE O-2-(DIETHYLAMINO)ETHYL OXIME; BENZHYDRYL DERIVATIVE; OXIME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER REGRESSION; CANCER STEM CELL; CELL FREE SYSTEM; CELL INVASION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; HUMAN CELL; MCF 7 CELL LINE; MIGRATION INHIBITION; MONOTHERAPY; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; CELL CYCLE; CELL MOTION; DRUG EFFECTS; PHYSIOLOGY; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZHYDRYL COMPOUNDS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; MICE; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; OXIMES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84907929436     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500873e     Document Type: Article

References (80)

1. Levitzki, A. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance Annu. Rev. Pharmacol. Toxicol. 2013, 53, 161-185
2. Huang, H. L.; Chen, Y. C.; Huang, Y. C.; Yang, K. C.; Pan, H.; Shih, S. P.; Chen, Y. J. Lapatinib induces autophagy, apoptosis and megakaryocytic differentiation in chronic myelogenous leukemia K562 cells PLoS One 2011, 6, e29014
3. Lainey, E.; Wolfromm, A.; Marie, N.; Enot, D.; Scoazec, M.; Bouteloup, C.; Leroy, C.; Micol, J. B.; De Botton, S.; Galluzzi, L.; Fenaux, P.; Kroemer, G. Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia Oncogene 2013, 32, 4331-4342
4. Lainey, E.; Wolfromm, A.; Sukkurwala, A. Q.; Micol, J. B.; Fenaux, P.; Galluzzi, L.; Kepp, O.; Kroemer, G. EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D3 in acute myeloid leukemia cells Cell Cycle 2013, 12, 2978-2991
5. Stegmaier, K.; Corsello, S. M.; Ross, K. N.; Wong, J. S.; Deangelo, D. J.; Golub, T. R. Gefitinib induces myeloid differentiation of acute myeloid leukemia Blood 2005, 106, 2841-2848
6. Fabian, M. A.; Biggs, W. H., 3rd; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lelias, J. M.; Mehta, S. A.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. A small molecule-kinase interaction map for clinical kinase inhibitors Nat. Biotechnol. 2005, 23, 329-336
7. Leggas, M.; Panetta, J. C.; Zhuang, Y.; Schuetz, J. D.; Johnston, B.; Bai, F.; Sorrentino, B.; Zhou, S.; Houghton, P. J.; Stewart, C. F. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo Cancer Res. 2006, 66, 4802-4807
8. Shi, Z.; Peng, X. X.; Kim, I. W.; Shukla, S.; Si, Q. S.; Robey, R. W.; Bates, S. E.; Shen, T.; Ashby, C. R., Jr.; Fu, L. W.; Ambudkar, S. V.; Chen, Z. S. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance Cancer Res. 2007, 67, 11012-11020
9. Aparicio-Gallego, G.; Blanco, M.; Figueroa, A.; Garcia-Campelo, R.; Valladares-Ayerbes, M.; Grande-Pulido, E.; Anton-Aparicio, L. New insights into molecular mechanisms of sunitinib-associated side effects Mol. Cancer Ther. 2011, 10, 2215-2223
10. Jacquel, A.; Herrant, M.; Legros, L.; Belhacene, N.; Luciano, F.; Pages, G.; Hofman, P.; Auberger, P. Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward the erythroid lineage FASEB J. 2003, 17, 2160-2162
11. Ling, Y. H.; Lin, R.; Perez-Soler, R. Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK Mol. Pharmacol. 2008, 74, 793-806
12. Newcomb, E. W.; Tamasdan, C.; Entzminger, Y.; Alonso, J.; Friedlander, D.; Crisan, D.; Miller, D. C.; Zagzag, D. Flavopiridol induces mitochondrial-mediated apoptosis in murine glioma GL261 cells via release of cytochrome c and apoptosis inducing factor Cell Cycle 2003, 2, 243-250
13. Premkumar, D. R.; Jane, E. P.; Pollack, I. F. Co-administration of NVP-AEW541 and dasatinib induces mitochondrial-mediated apoptosis through Bax activation in malignant human glioma cell lines Int. J. Oncol. 2010, 37, 633-643
14. Shaker, M. E.; Ghani, A.; Shiha, G. E.; Ibrahim, T. M.; Mehal, W. Z. Nilotinib induces apoptosis and autophagic cell death of activated hepatic stellate cells via inhibition of histone deacetylases Biochim. Biophys. Acta 2013, 1833, 1992-2003
15. Wesierska-Gadek, J.; Gueorguieva, M.; Horky, M. Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells Mol. Cancer Ther. 2005, 4, 113-124
16. Wu, J.; Min, R.; Wu, M.; Chen, W. Gefitinib induces mitochondrial-dependent apoptosis in Saccharomyces cerevisiae Mol. Med. Rep. 2011, 4, 357-362
17. Zhang, W.; Konopleva, M.; Ruvolo, V. R.; McQueen, T.; Evans, R. L.; Bornmann, W. G.; McCubrey, J.; Cortes, J.; Andreeff, M. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway Leukemia 2008, 22, 808-818
18. Sordella, R.; Bell, D. W.; Haber, D. A.; Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways Science 2004, 305, 1163-1167
19. Martin, P.; Oliver, S.; Kennedy, S. J.; Partridge, E.; Hutchison, M.; Clarke, D.; Giles, P. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects Clin. Ther. 2012, 34, 221-237
20. Li, Z.; Xu, M.; Xing, S.; Ho, W. T.; Ishii, T.; Li, Q.; Fu, X.; Zhao, Z. J. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth J. Biol. Chem. 2007, 282, 3428-3432
21. Higa, G. M.; Abraham, J. Lapatinib in the treatment of breast cancer Expert Rev. Anticancer Ther. 2007, 7, 1183-1192
22. Lin, N. U.; Winer, E. P.; Wheatley, D.; Carey, L. A.; Houston, S.; Mendelson, D.; Munster, P.; Frakes, L.; Kelly, S.; Garcia, A. A.; Cleator, S.; Uttenreuther-Fischer, M.; Jones, H.; Wind, S.; Vinisko, R.; Hickish, T. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab Breast Cancer Res. Treat. 2012, 133, 1057-1065
23. Kantarjian, H.; Giles, F.; Wunderle, L.; Bhalla, K.; O'Brien, S.; Wassmann, B.; Tanaka, C.; Manley, P.; Rae, P.; Mietlowski, W.; Bochinski, K.; Hochhaus, A.; Griffin, J. D.; Hoelzer, D.; Albitar, M.; Dugan, M.; Cortes, J.; Alland, L.; Ottmann, O. G. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL N. Engl. J. Med. 2006, 354, 2542-2551
24. Goldman, J. M.; Melo, J. V. Chronic myeloid leukemia - advances in biology and new approaches to treatment N. Engl. J. Med. 2003, 349, 1451-1464
25. Yokota, A.; Kimura, S.; Masuda, S.; Ashihara, E.; Kuroda, J.; Sato, K.; Kamitsuji, Y.; Kawata, E.; Deguchi, Y.; Urasaki, Y.; Terui, Y.; Ruthardt, M.; Ueda, T.; Hatake, K.; Inui, K.; Maekawa, T. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity Blood 2007, 109, 306-314
26. Gambacorti-Passerini, C.; Gasser, M.; Ahmed, S.; Assouline, S.; Scapozza, L. Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies Leukemia 2005, 19, 1267-1269
27. Clark, J. J.; Cools, J.; Curley, D. P.; Yu, J. C.; Lokker, N. A.; Giese, N. A.; Gilliland, D. G. Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518 Blood 2004, 104, 2867-2872
28. Nam, H. J.; Im, S. A.; Oh, D. Y.; Elvin, P.; Kim, H. P.; Yoon, Y. K.; Min, A.; Song, S. H.; Han, S. W.; Kim, T. Y.; Bang, Y. J. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer Mol. Cancer Ther. 2013, 12, 16-26
29. Boschelli, F.; Arndt, K.; Gambacorti-Passerini, C. Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia Eur. J. Cancer 2010, 46, 1781-1789
30. Raje, N.; Kumar, S.; Hideshima, T.; Roccaro, A.; Ishitsuka, K.; Yasui, H.; Shiraishi, N.; Chauhan, D.; Munshi, N. C.; Green, S. R.; Anderson, K. C. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma Blood 2005, 106, 1042-1047
31. Minutolo, F.; Sala, G.; Bagnacani, A.; Bertini, S.; Carboni, I.; Placanica, G.; Prota, G.; Rapposelli, S.; Sacchi, N.; Macchia, M.; Ghidoni, R. Synthesis of a resveratrol analogue with high ceramide-mediated proapoptotic activity on human breast cancer cells J. Med. Chem. 2005, 48, 6783-6786
32. Dawson, M. I.; Hobbs, P. D.; Peterson, V. J.; Leid, M.; Lange, C. W.; Feng, K. C.; Chen, G.; Gu, J.; Li, H.; Kolluri, S. K.; Zhang, X.; Zhang, Y.; Fontana, J. A. Apoptosis induction in cancer cells by a novel analogue of 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid lacking retinoid receptor transcriptional activation activity Cancer Res. 2001, 61, 4723-4730
33. Dong, Y.; Shi, Q.; Liu, Y. N.; Wang, X.; Bastow, K. F.; Lee, K. H. Antitumor agents. 266. Design, synthesis, and biological evaluation of novel 2-(furan-2-yl)naphthalen-1-ol derivatives as potent and selective antibreast cancer agents J. Med. Chem. 2009, 52, 3586-3590
34. Yasui, H.; Hideshima, T.; Ikeda, H.; Jin, J.; Ocio, E. M.; Kiziltepe, T.; Okawa, Y.; Vallet, S.; Podar, K.; Ishitsuka, K.; Richardson, P. G.; Pargellis, C.; Moss, N.; Raje, N.; Anderson, K. C. BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth Br. J. Hamaetol. 2007, 136, 414-423
35. Zhang, J.; Yang, P. L.; Gray, N. S. Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 2009, 9, 28-39
36. Xing, L.; Rai, B.; Lunney, E. A. Scaffold mining of kinase hinge binders in crystal structure database J. Comput.-Aided Mol. Des. 2014, 28, 13-23
37. Zhao, H.; Huang, D.; Caflisch, A. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics ChemMedChem 2012, 7, 1983-90
38. Tseng, C. H.; Chen, Y. L.; Yang, S. H.; Peng, S. I.; Cheng, C. M.; Han, C. H.; Lin, S. R.; Tzeng, C. C. Synthesis and antiproliferative evaluation of certain iminonaphtho[2,3-b]furan derivatives Bioorg. Med. Chem. 2010, 18, 5172-5182
39. Wang, T. C.; Chen, I. L.; Lu, P. J.; Wong, C. H.; Liao, C. H.; Tsiao, K. C.; Chang, K. M.; Chen, Y. L.; Tzeng, C. C. Synthesis, antiproliferative, and antiplatelet activities of oxime- and methyloxime-containing flavone and isoflavone derivatives Bioorg. Med. Chem. 2005, 13, 6045-6053
40. Tseng, C. H.; Chen, Y. L.; Lu, P. J.; Yang, C. N.; Tzeng, C. C. Synthesis and antiproliferative evaluation of certain indeno[1,2-c]quinoline derivatives Bioorg. Med. Chem. 2008, 16, 3153-3162
41. Srivastava, N.; Sangita, R. S.; Singh, M. M.; Dwivedi, A.; Kumar, A. Diaryl naphthyl methanes a novel class of anti-implantation agents Bioorg. Med. Chem. 2004, 12, 1011-1021
42. Chang, D. W.; Xing, Z.; Capacio, V. L.; Peter, M. E.; Yang, X. Interdimer processing mechanism of procaspase-8 activation EMBO J. 2003, 22, 4132-4142
43. Song, M. S.; Salmena, L.; Pandolfi, P. P. The functions and regulation of the PTEN tumour suppressor Nat. Rev. Mol. Cell Biol. 2012, 13, 283-296
44. Tamura, M.; Gu, J.; Matsumoto, K.; Aota, S.; Parsons, R.; Yamada, K. M. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN Science 1998, 280, 1614-1617
45. Bray, K.; Gillette, M.; Young, J.; Loughran, E.; Hwang, M.; Sears, J. C.; Vargo-Gogola, T. Cdc42 overexpression induces hyperbranching in the developing mammary gland by enhancing cell migration Breast Cancer Res. 2013, 15, R91
46. Fabre-Guillevin, E.; Malo, M.; Cartier-Michaud, A.; Peinado, H.; Moreno-Bueno, G.; Vallee, B.; Lawrence, D. A.; Palacios, J.; Cano, A.; Barlovatz-Meimon, G.; Charriere-Bertrand, C. PAI-1 and functional blockade of SNAI1 in breast cancer cell migration Breast Cancer Res. 2008, 10, R100
47. Beck, B.; Blanpain, C. Unravelling cancer stem cell potential Nat. Rev. Cancer 2013, 13, 727-738
48. Welte, Y.; Adjaye, J.; Lehrach, H. R.; Regenbrecht, C. R. Cancer stem cells in solid tumors: elusive or illusive? Cell Commun. Signal. 2010, 8, 6
49. Ginestier, C.; Hur, M. H.; Charafe-Jauffret, E.; Monville, F.; Dutcher, J.; Brown, M.; Jacquemier, J.; Viens, P.; Kleer, C. G.; Liu, S.; Schott, A.; Hayes, D.; Birnbaum, D.; Wicha, M. S.; Dontu, G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome Cell Stem Cell 2007, 1, 555-567
50. Douville, J.; Beaulieu, R.; Balicki, D. ALDH1 as a functional marker of cancer stem and progenitor cells Stem Cells Dev. 2009, 18, 17-25
51. Ren, F.; Sheng, W. Q.; Du, X. CD133: a cancer stem cells marker, is used in colorectal cancers World J. Gastroenterol. 2013, 19, 2603-2611
52. Gupta, P. B.; Onder, T. T.; Jiang, G.; Tao, K.; Kuperwasser, C.; Weinberg, R. A.; Lander, E. S. Identification of selective inhibitors of cancer stem cells by high-throughput screening Cell 2009, 138, 645-659
53. Wheeler, D. L.; Dunn, E. F.; Harari, P. M. Understanding resistance to EGFR inhibitors-impact on future treatment strategies Nat. Rev. Clin. Oncol. 2010, 7, 493-507
54. Habib, A. A.; Chun, S. J.; Neel, B. G.; Vartanian, T. Increased expression of epidermal growth factor receptor induces sequestration of extracellular signal-related kinases and selective attenuation of specific epidermal growth factor-mediated signal transduction pathways Mol. Cancer Res. 2003, 1, 219-233
55. Price, J. T.; Tiganis, T.; Agarwal, A.; Djakiew, D.; Thompson, E. W. Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3′-kinase and phospholipase C-dependent mechanism Cancer Res. 1999, 59, 5475-5478
56. Chazaud, B.; Ricoux, R.; Christov, C.; Plonquet, A.; Gherardi, R. K.; Barlovatz-Meimon, G. Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations Am. J. Pathol. 2002, 160, 237-246
57. Booy, E. P.; Henson, E. S.; Gibson, S. B. Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer Oncogene 2011, 30, 2367-2378
58. Gao, J.; Li, L.; Wu, M.; Liu, M.; Xie, X.; Guo, J.; Tang, H.; Xie, X. MiR-26a inhibits proliferation and migration of breast cancer through repression of MCL-1 PLoS One 2013, 8, e65138
59. Koehler, B. C.; Scherr, A. L.; Lorenz, S.; Urbanik, T.; Kautz, N.; Elssner, C.; Welte, S.; Bermejo, J. L.; Jager, D.; Schulze-Bergkamen, H. Beyond cell death-antiapoptotic Bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitro PLoS One 2013, 8, e76446
60. Han, E. K.; McGonigal, T.; Wang, J.; Giranda, V. L.; Luo, Y. Functional analysis of focal adhesion kinase (FAK) reduction by small inhibitory RNAs Anticancer Res. 2004, 24, 3899-3905
61. Sieg, D. J.; Hauck, C. R.; Ilic, D.; Klingbeil, C. K.; Schaefer, E.; Damsky, C. H.; Schlaepfer, D. D. FAK integrates growth-factor and integrin signals to promote cell migration Nat. Cell Biol. 2000, 2, 249-256
62. George, A. J.; Hannan, R. D.; Thomas, W. G. Unravelling the molecular complexity of GPCR-mediated EGFR transactivation using functional genomics approaches FEBS J. 2013, 280, 5258-5268
63. Fischer, O. M.; Hart, S.; Gschwind, A.; Ullrich, A. EGFR signal transactivation in cancer cells Biochem. Soc. Trans. 2003, 31, 1203-1208
64. Britten, C. D. Targeting ErbB receptor signaling: a pan-ErbB approach to cancer Mol. Cancer Ther. 2004, 3, 1335-1342
65. Gong, Y.; Somwar, R.; Politi, K.; Balak, M.; Chmielecki, J.; Jiang, X.; Pao, W. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas PLoS Med. 2007, 4, e294
66. McKillop, D.; Partridge, E. A.; Kemp, J. V.; Spence, M. P.; Kendrew, J.; Barnett, S.; Wood, P. G.; Giles, P. B.; Patterson, A. B.; Bichat, F.; Guilbaud, N.; Stephens, T. C. Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor Mol. Cancer Ther. 2005, 4, 641-649
67. Yan, Y.; Lu, Y.; Wang, M.; Vikis, H.; Yao, R.; Wang, Y.; Lubet, R. A.; You, M. Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer Mol. Cancer Res. 2006, 4, 971-981
68. Boehmerle, W.; Muenzfeld, H.; Springer, A.; Huehnchen, P.; Endres, M. Specific targeting of neurotoxic side effects and pharmacological profile of the novel cancer stem cell drug salinomycin in mice J. Mol. Med. (Berlin) 2014, 92, 889-900
69. Ojo, O. O.; Bhadauria, S.; Rath, S. K. Dose-dependent adverse effects of salinomycin on male reproductive organs and fertility in mice PLoS One 2013, 8, e69086
70. Manna, P. P.; Frazier, W. A. CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A Cancer Res. 2004, 64, 1026-1036
71. Chakravarti, B.; Siddiqui, J. A.; Dwivedi, S. K.; Deshpande, S.; Samanta, K.; Bhatta, R. S.; Panda, G.; Prabhakar, Y. S.; Konwar, R.; Sanyal, S.; Chattopadhyay, N. Specific targeting of insulin-like growth factor 1 receptor signaling in human estrogen dependent breast cancer cell by a novel tyrosine-based benzoxazepine derivative Mol. Cell. Endocrinol. 2011, 338, 68-78
72. Chakravarti, B.; Maurya, R.; Siddiqui, J. A.; Bid, H. K.; Rajendran, S. M.; Yadav, P. P.; Konwar, R. In vitro anti-breast cancer activity of ethanolic extract of Wrightia tomentosa: role of pro-apoptotic effects of oleanolic acid and urosolic acid J. Ethnopharmacol. 2012, 142, 72-79
73. Konecny, G. E.; Venkatesan, N.; Yang, G.; Dering, J.; Ginther, C.; Finn, R.; Rahmeh, M.; Fejzo, M. S.; Toft, D.; Jiang, S. W.; Slamon, D. J.; Podratz, K. C. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells Br. J. Cancer 2008, 98, 1076-1084
74. Byon, C. H.; Hardy, R. W.; Ren, C.; Ponnazhagan, S.; Welch, D. R.; McDonald, J. M.; Chen, Y. Free fatty acids enhance breast cancer cell migration through plasminogen activator inhibitor-1 and SMAD4 Lab. Invest. 2009, 89, 1221-1228
75. Jiang, W. G.; Hiscox, S. E.; Parr, C.; Martin, T. A.; Matsumoto, K.; Nakamura, T.; Mansel, R. E. Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells Clin. Cancer Res. 1999, 5, 3695-3703
76. Parr, C.; Sanders, A. J.; Davies, G.; Martin, T.; Lane, J.; Mason, M. D.; Mansel, R. E.; Jiang, W. G. Matriptase-2 inhibits breast tumor growth and invasion and correlates with favorable prognosis for breast cancer patients Clin. Cancer Res. 2007, 13, 3568-3576
77. Dontu, G.; Jackson, K. W.; McNicholas, E.; Kawamura, M. J.; Abdallah, W. M.; Wicha, M. S. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells Breast Cancer Res. 2004, 6, R605-615
78. Singh, N.; Yadav, M.; Singh, A. K.; Kumar, H.; Dwivedi, S. K.; Mishra, J. S.; Gurjar, A.; Manhas, A.; Chandra, S.; Yadav, P. N.; Jagavelu, K.; Siddiqi, M. I.; Trivedi, A. K.; Chattopadhyay, N.; Sanyal, S. Synthetic FXR agonist GW4064 is a modulator of multiple G protein-coupled receptors Mol. Endocrinol. 2014, 28, 659-673
79. Spears, G.; Sneyd, J. G.; Loten, E. G. A method for deriving kinetic constants for two enzymes acting on the same substrate Biochem. J. 1971, 125, 1149-1151
80. Foltyn, V. N.; Zehl, M.; Dikopoltsev, E.; Jensen, O. N.; Wolosker, H. Phosphorylation of mouse serine racemase regulates D-serine synthesis FEBS Lett. 2010, 584, 2937-2941